NCT04703868

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Yungjin Pharm. Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Detailed description

This study is to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	Rabeprazole Sodium 10mg	Part A: 1 tablet administered before the breakfast during 7 days
DRUG	Rabeprazole Sodium 20mg	Part B: 1 tablet administered before the breakfast during 7 days

Timeline

• Start date: 2021-01-13
• Primary completion: 2021-06-01
• Completion: 2021-06-14
• First posted: 2021-01-11
• Last updated: 2024-01-24

Locations

1 site across 1 country: South Korea